Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

CompagOs

CompagOs is developing a blood-based test to help oncologists detect bone metastases early with mineralized bone models.
2023
1-10
1-10
Hünenberg, Zug, Switzerland
  • Oncology

Investment Funding

Total Funding Amount

$282.9K

Last Funding Amount

$100.0K

Last Funding Date

02-09-2024

Startup Stage

Convertible Note

Lead Investors

Venture Kick

About

Our mission is to help oncologists select the most effective treatment for patients with cancer in the bone. Leveraging 3D bioprinting technology, we recreate the unique cancerous condition of the patient’s bone in a controlled laboratory environment, enabling us to assess different drug reactions and determine personalized treatment options. By surpassing the limitations of conventional animal and 2D models, we also envision our solution as a powerful tool for drug development, accurately reproducing human physiological conditions and driving innovation in the field. Together, we aim to revolutionize cancer treatment by offering personalized solutions that improve patient outcomes and advance the field of oncology.

Something missing or incorrect on this page? Help us enrich this information